Remission of major depressive disorder without adverse events: A comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1089-1096

  Signorovitch, James ^a   Ramakrishnan, Karthik ^a   Ben Hamadi, Rym ^a   Yu, Andrew P ^a   Wu, Eric Q ^a   Dworak, Heather ^b   Erder, M Haim ^b  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Benefit risk; Escitalopram; Major depressive disorder Montgomery sberg Depression Rating Scale; SNRI

Indexed keywords

DULOXETINE; ESCITALOPRAM; VENLAFAXINE;

ADULT; ARTICLE; BLINDNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PATIENT CODING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; REMISSION INDUCTION; SEROTONIN; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956123734     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.567255     Document Type: Article

References (42)

1. Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105 (Pubitemid 37432885)
2. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914-19 (Pubitemid 19208948)
3. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Massachusetts: Harvard University Press. 1996
4. Eaton WW, Martins SS, Nestadt G, et al. The burden of mental disorders [published online ahead of print September 19, 2008]. Epidemiol Rev 2008;30:1-14. doi:10.1093/epirev/mxn011
5. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75 (Pubitemid 41270106)
6. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22-33 (Pubitemid 36675445)
7. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNSSpectr 2005;10:732-47 (Pubitemid 41443048)
8. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders\III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(3 Suppl B):S55-87 (Pubitemid 28556670)
9. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-26 (Pubitemid 41341413)
10. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50 (Pubitemid 32816947)
11. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005;65:2379-404 (Pubitemid 41573609)
12. Bielski, RJ, Ventura, D, Chang, CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
13. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-92 (Pubitemid 46919700)
14. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64 (Pubitemid 38721171)
15. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14 (Pubitemid 47122170)
16. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet 2009;373:746-58
17. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58:393-8 (Pubitemid 27438691)
18. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15 (Pubitemid 34456358)
19. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90 (Pubitemid 35254112)
20. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder. J Clin Psychiatry 2002;63:225-31
21. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression. A double-blind placebo controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99 (Pubitemid 38944137)
22. Detke MJ, Wiltse C, Mallinckrodt C, et al. Duloxetine in the acute and long term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70 (Pubitemid 39626894)
23. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-81 (Pubitemid 30058219)
24. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404 (Pubitemid 34499333)
25. Mallinckrodt CH, Prakash A, Houston JP, et al. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007;56:73-85 (Pubitemid 351340017)
26. Nierenberg AA, GreistJH, Mallinkrodt C, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007; 23:401-16 (Pubitemid 46333388)
27. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309 (Pubitemid 44162482)
28. Asnis G, Tsai J, Mao Y. Fixed-dose comparison of escitalopram and duloxetine in severely depressed patients (NCT00384436). Poster presented at Collegium Internationale Neuro-Psychopharmacologicum XXVI; July 15, 2008; Munich, Germany
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association, 2000
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9 (Pubitemid 9136500)
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
32. Demyttenaere K, De Fruyt J. Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 2003;72:61-70 (Pubitemid 36302474)
33. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002;36:578-84 (Pubitemid 34270268)
34. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304 (Pubitemid 37076320)
35. Kennedy S, Mclntyre R, Fallu A, et al. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-80 (Pubitemid 34988907)
36. Manning C, Marr J. 'Real-life burden of depression' surveys-GP and patient perspectives on treatment and management of recurrent depression. Curr Med Res Opin 2003;19:526-31 (Pubitemid 37122046)
37. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure' number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996;25:704-12 (Pubitemid 26290051)
38. EntsuahR, ChitraR. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997;33:671-6
39. Entsuah R, Gorman, JM. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res 2002;36:111-18 (Pubitemid 34218951)
40. Pritchett YL, Tamura R. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method. Pharm Stat 2008; 7:170-8
41. Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003; 62:316-21 (Pubitemid 36363436)
42. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008;300:2417-19